Close

Analyst Ratings for BioXcel Therapeutics (BTAI)

BTAI Rating Summary

BTAI Price Target Summary

* Over Last 12-Mos
  |   Expand Research on BTAI
Overall Rating: BUY   Rating Trend: =   Avg. $ Target: $12.29 (+300.2%) * Over Last 12-Mos
Rating Score: 5 / 10   Percentile Rank: 53%
Date Firm Analyst Type Rating
(Past)
PT
(Past)
Start $
(End $)
% Chg. Details
2/21/2024 UBS Colin Bristow Downgrade Neutral
(Buy)
4.00
(9.00)
3.51
(3.07)
-12.54% Details
10/4/2023 Truist Securities Robyn Karnauskas Downgrade Hold
(Buy)
N/A
(N/A)
2.34
(3.07)
31.2% Details
Like BTAI Ratings? Also take a look at STX, BAX, IBRX, CBAY

BTAI Ratings News